ArticleInternational journal of clinical and experimental pathology2017
Downregulation of miR-381 is associated with poor prognosis in papillary thyroid carcinoma.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Circulating microRNAs and Clinicopathological Findings of Papillary Thyroid Cancer: A Systematic Review.In vivo (Athens, Greece)Pooled it
- Investigation of the Expression Levels of miR-383, miR-381, and miR-141 miRNAs as Diagnostic Biomarkers in Acute Myeloid Leukemia.International journal of laboratory hematology · 2026Article
- The expression of miR-381-3p in acute myeloid leukemia and its effect on corresponding cell proliferation and apoptosis.Discover oncology · 2025Article
- Clinical significance of dysregulation of miR-381 in pediatric acute myeloid leukemia.European journal of medical research · 2020Article
- The Prognostic Value of MicroRNAs in Thyroid Cancers-A Systematic Review and Meta-Analysis.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating microRNAs (miRNAs) are potential biomarkers for papillary thyroid carcinoma (PTC). The aim of this study was to evaluate the diagnostic and prognostic value of serum miR-381 in PTC. A total of 87 patients with PTC, 50 cases with benign thyroid nodules (BTN) and 50 healthy volunteers were enrolled. The expression levels of serum miR-381 were measured using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The results indicated that serum miR-381 expression was significantly decreased in PTC patients compared to that of BTN patients or healthy controls. Moreover, serum miR-381 showed good performance to differentiate PTC cases from controls. Next, reduced serum miR-381 expression was positively correlated with aggressive clinical features and shorter overall survival. Furthermore, serum miR-381 levels were greatly elevated in 21 patients with advanced-stage (stage III/IV) PTC after surgery. Finally, univariate and multivariate Cox regression analysis confirmed that miR-381 in serum was an independent prognostic indicator for OS in PTC patients. Collectively, serum miR-381 might serve as a non-invasive biomarker for the diagnosis and prognosis of PTC.
Indexed as
Identifiers
31966518PMC6966045W3027715866What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.